Altreno® (tretinoin) Lotion, 0.05% is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
Altreno is for topical use only. Not for ophthalmic, oral, or intravaginal use.
Skin Irritation: Patients using Altreno may experience application site dryness, pain, erythema, irritation, and exfoliation.
Patients using Altreno may experience application site dryness, pain, erythema, irritation, and exfoliation. Depending upon the severity of these adverse reactions, instruct patients to use a moisturizer, reduce the frequency of the application of Altreno, or discontinue use. Avoid application of Altreno to eczematous or sunburned skin.
Minimize unprotected exposure to ultraviolet light, including sunlight and sunlamps. Warn patients with frequent sun exposure and those with inherent sensitivity to sunlight to exercise caution. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.
Altreno contains soluble fish proteins. Use with caution in patients with known sensitivity or allergy to fish. Advise patients to contact their healthcare provider if they develop pruritus or urticaria.
The most common adverse reactions in clinical trials were application site dryness (4%), pain (3%), erythema (2%), irritation (1%) and exfoliation (1%).
It is not known whether topical administration of tretinoin could result in sufficient systemic absorption to produce detectable concentrations in human milk. The developmental health benefits of breastfeeding should be considered along with the mother’s clinical need for Altreno and any potential adverse effects on the breastfed child from Altreno.
To report suspected adverse reactions, contact Customer Service at 1-800-321-4576 or the FDA at 1-800-FDA-1088 or fda.gov/medwatch.
Patients using Altreno may experience application site dryness, pain, erythema, irritation, and exfoliation. Depending upon the severity of these adverse reactions, instruct patients to use a moisturizer, reduce the frequency of the application of Altreno, or discontinue use. Avoid application of Altreno to eczematous or sunburned skin.
Minimize unprotected exposure to ultraviolet light, including sunlight and sunlamps. Warn patients with frequent sun exposure and those with inherent sensitivity to sunlight to exercise caution. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.
Altreno contains soluble fish proteins. Use with caution in patients with known sensitivity or allergy to fish. Advise patients to contact their healthcare provider if they develop pruritus or urticaria.
The most common adverse reactions in clinical trials were application site dryness (4%), pain (3%), erythema (2%), irritation (1%) and exfoliation (1%).
It is not known whether topical administration of tretinoin could result in sufficient systemic absorption to produce detectable concentrations in human milk. The developmental health benefits of breastfeeding should be considered along with the mother’s clinical need for Altreno and any potential adverse effects on the breastfed child from Altreno.
To report suspected adverse reactions, contact Customer Service at 1-800-321-4576 or the FDA at 1-800-FDA-1088 or fda.gov/medwatch.
Altreno® (tretinoin) Lotion, 0.05% is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
Altreno is for topical use only. Not for ophthalmic, oral, or intravaginal use.
Skin Irritation: Patients using Altreno may experience application site dryness, pain, erythema, irritation, and exfoliation.
Using hydrating properties of glycerin, collagen, and sodium hyaluronate, Altreno helps reduce irritation associated with tretinoin and boost skin barrier function.
The barrier-supporting effects of the Altreno vehicle are beneficial since a properly functioning barrier is essential to re-establishing healthy skin.
Patients with different skin types will likely appreciate the hydrating effects of an easily applied topical lotion.*
*Like all tretinoins, Altreno may cause irritation.
The Altreno polymeric honeycomb mesh helps provide a uniform distribution of both the micronized tretinoin as well as the moisturizing and hydrating ingredients (sodium hyaluronate, soluble collagen, glycerin).
Tretinoin is a clinical-strength vitamin A derivative proven to treat acne to improve the quality and texture of skin.
Sodium Hyaluronate, a form of Hyaluronic Acid, helps keep skin moisturized throughout the day.
Naturally hydrate with marine collagen, derived from sole fish*, which moisturizes and hydrates skin.
Glycerin hydrates and can help protect skin from irritation and may contribute to the healing process.
*Use with caution in patients with known sensitivity or allergy to fish. Advise patients to contact their healthcare provider if they develop pruritus or urticaria.
The formulation of Altreno is what makes it unique. The lotion vehicle contains hydrating ingredients delivered by a honeycomb mesh to help counterbalance the regular side effects of tretinoin.*
*Adapted from Kircik et al. (2019). Skin barrier protection of the lotion was assessed through corneometry in 30 female healthy volunteers (aged 35-65 years) over 24 hours; the vehicle was applied to the volar forearm, with an untreated site serving as a control. Measurements using Corneometer® were taken at baseline, 15 and 30 minutes, and 1, 2, 3, 8, and 24 hours post-application. Mean baseline corneometry scores 29.2 ± 2.4 and 28.1 ± 2.7 units (test material and untreated control, respectively).
The formulation of Altreno is what makes it unique. The lotion vehicle contains hydrating ingredients delivered by a honeycomb mesh to help counterbalance the regular side effects of tretinoin.*
*Adapted from Kircik et al. (2019). Skin barrier protection of the lotion was assessed through TEWL in 30 female healthy volunteers (aged 35-65 years) over 24 hours; the vehicle was applied to the volar forearm, with an untreated site serving as a control. Measurements using Tewameter® were taken at baseline, 15 and 30 minutes, and 1, 2, 3, 8, and 24 hours post-application. Mean baseline TEWL scores were 12.32 ± 0.43 and 12.42 ± 0.44 g/hm2, respectively.
Physicians surveyed agreed that the lotion vehicle (n=349):*
*Results from a perception survey of healthcare professionals who tried the lotion vehicle.
A total of 349 prescribers with practices in the United States tried the Altreno lotion vehicle and completed the survey.1
Patients surveyed about the lotion vehicle found (n=15):
Actual patients from a clinical study after 12 weeks of treatment. Photos have not been retouched. Individual results may vary.
Baseline
Week 12
Baseline 1
Week 12
Baseline 1
Week 12
Baseline 1
Week 12*Two Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group studies comparing the efficacy and safety of Altreno lotion (tretinoin 0.05%) once daily to the lotion vehicle alone in patients 9 years and older with moderate-to-severe acne vulgaris.
Treatment-related adverse events reported by ≥1% of patients through week 12 (Altreno Lotion [n=767] vs. vehicle lotion [n=783], respectively:*
Application site:
*Two Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group studies comparing the efficacy and safety of Altreno Lotion (tretinoin 0.05%) once daily to the lotion vehicle alone in patients 9 years and older with moderate-to-severe acne vulgaris.
In the Tyring et al. (2018) safety population, 12/767 (1.6%) of patients in the Altreno group discontinued due to treatment emergent adverse event(s) (TEAE). None of the patients in the vehicle group discontinued due to a TEAE.*
*Two Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group studies comparing the efficacy and safety of Altreno Lotion (tretinoin 0.05%) once daily to the lotion vehicle alone in patients 9 years and older with moderate-to-severe acne vulgaris.
In the Tyring et al. (2018) safety population, 12/767 (1.6%) of patients in the Altreno group discontinued due to treatment emergent adverse event(s) (TEAE). None of the patients in the vehicle group discontinued due to a TEAE.*
*Two Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group studies comparing the efficacy and safety of Altreno Lotion (tretinoin 0.05%) once daily to the lotion vehicle alone in patients 9 years and older with moderate-to-severe acne vulgaris.
01
Altreno 20g
02
Altreno 45g
Altreno® (tretinoin) Lotion, 0.05% is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.
Altreno is for topical use only. Not for ophthalmic, oral, or intravaginal use.
Skin Irritation: Patients using Altreno may experience application site dryness, pain, erythema, irritation, and exfoliation.
Patients using Altreno may experience application site dryness, pain, erythema, irritation, and exfoliation. Depending upon the severity of these adverse reactions, instruct patients to use a moisturizer, reduce the frequency of the application of Altreno, or discontinue use. Avoid application of Altreno to eczematous or sunburned skin.
Minimize unprotected exposure to ultraviolet light, including sunlight and sunlamps. Warn patients with frequent sun exposure and those with inherent sensitivity to sunlight to exercise caution. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.
Altreno contains soluble fish proteins. Use with caution in patients with known sensitivity or allergy to fish. Advise patients to contact their healthcare provider if they develop pruritus or urticaria.
The most common adverse reactions in clinical trials were application site dryness (4%), pain (3%), erythema (2%), irritation (1%) and exfoliation (1%).
It is not known whether topical administration of tretinoin could result in sufficient systemic absorption to produce detectable concentrations in human milk. The developmental health benefits of breastfeeding should be considered along with the mother’s clinical need for Altreno and any potential adverse effects on the breastfed child from Altreno.
To report suspected adverse reactions, contact Customer Service at 1-800-321-4576 or the FDA at 1-800-FDA-1088 or fda.gov/medwatch.
Altreno is a powerful Rx product, which means it requires a prescription. We can help you get in touch with a healthcare provider in two easy ways:
1. Online consultation
2. In-person visit
